The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important.
- Mallinckrodt PLC (NYSE:MNK) is expected to release Phase 4 interim Acthar data for multiple sclerosis at the end of May, rheumatoid arthritis in June and systemic lupus erythematosus at some point in the second quarter.
- Mylan NV (NASDAQ:MYL)’s Neulasta and Advair biosimilars have June 4 and June 27 Target Action Dates, respectively. Cantor forecast June oral arguments for challenged Restasis patents and a second-quarter launch of Cimduo.
- Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA)’s injectable CGRP fremanezumab has a June 16 PDUFA date, and Cantor anticipates approval and launch before the end of the year.
- Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is expected to secure approval for Duobrii June 18 and release Phase 3 data for IPD-123 in the second quarter.
- Arsanis Inc (NASDAQ:ASNS) will report Phase 2 interim results for ASN100 in late June.
- Dermira Inc (NASDAQ:DERM)’s DRM04 has a June 30 PDUFA date, and management will host an investor day May 24.
- Nabriva Therapeutics PLC - ADR (NASDAQ:NBRV) is expected to report Phase 3 Lefamulin data in late spring.
- Amneal Pharmaceuticals Inc (NYSE:AMRX) plans to launch generic Welchol and begin its Rytary trial with Teva sometime in the second quarter.
- Aclaris Therapeutics Inc (NASDAQ:ACRS) is expected to release Phase 2 data for ATI-502 in the second quarter.
- Shire PLC (ADR) (NASDAQ:SHPG) anticipates approval for its Covington manufacturing facility in June or July.
- Heron Therapeutics Inc (NASDAQ:HRTX) expects top-line results for its HTX-011 studies toward the end of the second quarter.
- Cidara Therapeutics Inc (NASDAQ:CDTX) plans to announce a development candidate midyear.
- Spero Therapeutics Inc (NASDAQ:SPRO) will report Phase 1 data for SPR994 by mid-2018 with the second quarter bringing results for a Phase 1b study of SPR741 and preclinical study of SPR206. SPR994 will begin a Phase 3 trial at the end of the year.
- Theravance Biopharma Inc (NASDAQ:TBPH) will report Phase 2a data for TD-9855 by the end of July, has a Nov. 13 PDUFA date for TD-4208 and will begin reporting Phase 1b data for its JAK inhibitor in the back half of 2018.
- Allergan plc (NYSE:AGN) has a PDUFA date for Esmya in August; anticipates Sarecycline approval and the release of Abicipar Phase 3 data in the second half of 2018; and will report Rapastinel Phase 3 data in 2019. Cantor Fitzgerald expects Phase 2b data for oral CGRP atogepant and Phase 2 data for pilocarpine/oxymetazoline in the second half of 2018.
- Endo International PLC (NASDAQ:ENDP) will report Phase 3 data for Xiaflex by the first quarter of 2019.
- Paratek Pharmaceuticals Inc (NASDAQ:PRTK) will report Phase 2 data for Omadacycline cUTI in the second half of 2019.
- Opko Health Inc. (NASDAQ:OPK) is expected to release interim Phase 2b data for OPK88004.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Related Links:
Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.